NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange

Core Viewpoint - NervGen Pharma Corp. has announced its decision to voluntarily delist its common shares from the TSX Venture Exchange, effective March 16, 2026, to streamline operations and focus on clinical development for its lead therapeutic candidate, NVG-291 [1][2]. Group 1: Delisting Decision - The voluntary delisting reflects NervGen's maturity as it enters late-stage development for NVG-291 and aims to reduce costs and administrative burdens associated with maintaining a dual listing [2]. - The decision was approved by the Company's Board of Directors, and no shareholder approval is required due to the presence of an acceptable alternative market [4]. Group 2: Shareholder Impact - All shareholders, including Canadian shareholders, will retain full trading access to their common shares on Nasdaq, and no action is required from them regarding the delisting [3][7]. Group 3: Financial Program Termination - In connection with the delisting, the Company has terminated its at-the-market equity program, which had issued 245 common shares at a weighted average price of $6.20, resulting in aggregate net proceeds of $1,489 [5]. Group 4: Company Overview - NervGen Pharma is a clinical-stage biopharmaceutical company focused on developing neuroreparative therapeutics for spinal cord injury and other neurological conditions, with its lead candidate NVG-291 showing promise in clinical trials [6]. - NVG-291 has received Fast Track designation from the FDA and Orphan Drug designation from the EMA, indicating its potential significance in treating spinal cord injuries [6].